Scotland’s SMC OKs Drugs For Cancer & Plaque Psoriasis
But the HTA body has rejected two other anticancer medicines
Executive Summary
The Scottish Medicines Consortium has OKd Keytruda, Decapeptyl, Yescarta and Skyrizi after patient access schemes were agreed that improved their cost-effectiveness. But Perjeta and Xtandi were rejected because the companies made no solid economic case for NHS funding.